圣湘生物科技股份有限公司 章程 （2024 年第一次临时股东大会审议通过） 二〇二四年十一月 | 第一章 | 总则 | 2 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 3 | | 第三章 | 股份 | 4 | | 第一节 | 股份发行 4 | | | 第二节 | 股份增减和回购 7 | | | 第三节 | 股份转让 8 | | | 第四章 | 股东和股东大会 | 9 | | 第一节 | 股东 9 | | | 第二节 | 股东大会的一般规定 12 | | | 第三节 | 股东大会的召集 16 | | | 第四节 | 股东大会的提案与通知 18 | | | 第五节 | 股东大会的召开 20 | | | 第六节 | 股东大会的表决和决议 23 | | | 第五章 | 董事会 | 28 | | 第一节 | 董事 28 | | | 第二节 | 董事会 33 | | | 第六章 | 总经理及其他高级管理人员 | 39 | | 第七章 | 监事会 | 41 | | 第一节 | 监事 41 | | | 第二节 | 监事会 42 | | | 第八章 | 财务会计制度、利润分配和审计 | 44 ...

证券代码：688289 证券简称：圣湘生物 公告编号：2024-066 圣湘生物科技股份有限公司 关于变更注册资本、修订《公司章程》并办理工 商变更登记的公告 根据公司 2024 年第一次临时股东大会的授权，本次修订无需再提交股东大会审 议，公司将及时向市场监督管理部门办理《公司章程》的变更或备案等相关手续，上 述变更最终以市场监督管理部门核准的内容为准。 二、《公司章程》的修订情况 基于上述总股本和注册资本的变更情况，根据相关规定和要求，拟对《公司章程》 中的相关条款进行修订。具体修订内容如下： | 序号 | 修订前 | | 修订后 | | | --- | --- | --- | --- | --- | | 1 | 第 六 条 | 公 司 注 册 资 本 为 人 民 币 | 第 六 条 | 公 司 注 册 资 本 为 人 民 币 | | | 583,388,006 | 元 | 582,388,006 | 元 | | | 第二十条 公司的股份总数为 | 583,388,006 | 第二十条 公司的股份总数为 | 582,388,006 | | --- | --- | --- | --- | --- | | 2 ...

Key Points Industry and Company - **Company**: A life science company specializing in in vitro diagnostics and transitioning to an ecosystem platform. - **Industry**: In vitro diagnostics, medical technology, and healthcare. Core Views and Arguments - **Ecosystem Building**: The company has been actively building an ecosystem by collaborating with renowned universities, top talent from multinational companies, and industry leaders. This includes hosting events like the "Digital Empowerment Ecosystem Sharing and Intelligence Partner Conference" with participants like Huawei Cloud and JD Health. - **Performance**: The company has achieved significant growth, with cumulative cash dividends exceeding 2 billion yuan and share buybacks totaling nearly 600 million yuan. - **Strategic Focus**: The company is focusing on expanding its product portfolio, enhancing digital capabilities, and exploring new markets both domestically and internationally. - **Globalization**: The company is actively expanding its international presence, targeting key markets in Southeast Asia, Europe, and the United States. Other Important Points - **Product Innovation**: The company has been investing in product innovation, including new products in the infectious disease, respiratory, and women's health segments. - **Digitalization**: The company is focusing on digitalization, including the development of new systems and solutions to improve efficiency and accessibility. - **Regulatory Environment**: The company is closely monitoring regulatory changes and adapting its strategies accordingly. - **Investor Relations**: The company is committed to maintaining strong relationships with investors and providing transparent communication. References - [1] - [2] - [3] - [4] - [5] - [6] - [7] - [8] - [9] - [10] - [11] - [12] - [13] - [14] - [15] - [16] - [17] - [18] - [19] - [20] - [21] - [22] - [23] - [24] - [25] - [26] - [27] - [28] - [29] - [30] - [31] - [32] - [33] - [34] - [35] - [36] - [37]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 为提高公司长期投资价值，提升每股收益水平，进一步增强投资者信心，结合公司实际情况，圣湘生 物科技股份有限公司（以下简称"公司"）本次将注销回购专用证券账户中的股份共100万股，占注销前 公司总股本583,388,006股的比例为0.17%。本次注销完成后，公司总股本将由583,388,006股减少为 582,388,006股，注册资本将由583,388,006元减少为582,388,006元。 ● 回购股份注销日：2024年10月28日 公司于2024年8月16日召开第二届董事会2024年第六次会议及第二届监事会2024年第四次会议，并于 2024年9月3日召开2024年第一次临时股东大会，审议通过了《圣湘生物科技股份有限公司关于变更部分 回购股份用途并注销暨减少注册资本的议案》。为提高公司长期投资价值，提升每股收益水平，进一步 增强投资者信心，结合公司实际情况，同意公司将存放于回购专用证券账户中原用于员工持股计划或股 权激励的100万股予以注销以减少注册 ...

证券代码：688289 证券简称：圣湘生物 公告编号：2024-064 圣湘生物科技股份有限公司 关于控股股东、实际控制人及其一致行动人权益 变动累计达到 1%的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本次权益变动后，公司控股股东、实际控制人戴立忠先生持有公司的股份数量 为 190,205,090 股，占公司总股本的比例增加至 32.66%；其与一致行动人（以下或合 称"信息披露义务人"）合计持有公司的股份数量为 242,236,264 股，合计占公司总股 本的比例增加至 41.59%； 本次权益变动不会导致公司的控股股东及实际控制人发生变化。 信息披露义务人 1 姓 名 戴立忠 性 别 男 国 籍 中国 信息披露义务人 2 企业名称 湖南圣维投资管理有限公司（以下简称"圣维投资"） 企业类型 有限责任公司 主要股东 戴立忠持有 86.96%的股份 注 册 地 湖南省长沙市 统一社会信用代码 9143010057222929XP 信息披露义务人 3 企业名称 湖南圣维鼎立管理咨询中心（有限合伙）（以下简 ...

证券代码：688289 证券简称：圣湘生物 公告编号：2024-063 圣湘生物科技股份有限公司 关于回购股份注销完成暨股份变动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 为提高公司长期投资价值，提升每股收益水平，进一步增强投资者信心，结合 公司实际情况，圣湘生物科技股份有限公司（以下简称"公司"）本次将注销回购专 用证券账户中的股份共100万股，占注销前公司总股本583,388,006股的比例为0.17%。 本次注销完成后，公司总股本将由 583,388,006 股减少为 582,388,006 股，注册资本将 由 583,388,006 元减少为 582,388,006 元。 回购股份注销日：2024 年 10 月 28 日 公司于 2024 年 8 月 16 日召开第二届董事会 2024 年第六次会议及第二届监事会 2024 年第四次会议，并于 2024 年 9 月 3 日召开 2024 年第一次临时股东大会，审议通 过了《圣湘生物科技股份有限公司关于变更部分回购股份用途并注销暨减少注册资本 ...

Investment Rating - The report maintains a "Buy-A" investment rating for the company with a 12-month target price of 28.99 CNY, which corresponds to a dynamic price-to-earnings ratio of 35 times for 2025 [6]. Core Views - The company has demonstrated continuous high-speed growth, achieving a revenue of 1.033 billion CNY in the first three quarters of 2024, representing a year-on-year increase of 63.24%. The net profit attributable to shareholders reached 195 million CNY, with a profit margin of 18.9% [1]. - Despite a significant increase in expense ratios in the third quarter, the company managed to maintain stable absolute values for its expenses, and effective cash collection led to a decrease in accounts receivable [2]. - The company has received approvals for multiple new products, particularly in the respiratory field, and is expected to perform well in the fourth quarter due to the seasonal increase in respiratory infections [3]. Summary by Sections Financial Performance - In Q3 2024, the company reported a revenue of 316 million CNY, a year-on-year increase of 54.0%, and a net profit of 38.72 million CNY, with a profit margin of 12.3% [1]. - The gross profit margin reached 78.04% in Q3, an increase of 5.37 percentage points compared to Q2 [5]. Expense Management - The company experienced a significant rise in expense ratios in Q3, with sales, management, and R&D expense ratios increasing by 5.72, 0.86, and 3.83 percentage points, respectively. However, the absolute values of expenses remained relatively stable across Q1, Q2, and Q3 [2]. Product Development and Market Outlook - The company has received approvals for several new products, including nucleic acid test kits for respiratory viruses and HPV test kits, which are expected to contribute positively to revenue in the upcoming quarters [3]. - The report anticipates that the company will continue its revenue growth trend in Q4, driven by the seasonal increase in respiratory infections [4]. Revenue and Profit Forecast - The company is projected to achieve revenue growth rates of 51.5%, 32.2%, and 26.7% for 2024, 2025, and 2026, respectively. The net profit is expected to grow by -5.5%, 40.6%, and 41.5% during the same period, indicating strong growth potential [4].

Financial Performance - The company's operating revenue for Q3 2024 reached ¥315,623,085.49, representing a year-on-year increase of 54.08%[2] - The net profit attributable to shareholders for Q3 2024 was ¥38,721,202.19, showing a significant decrease of 81.39% compared to the same period last year[2] - The basic earnings per share for Q3 2024 was ¥0.07, down 80.00% from the same period last year[3] - The company reported a significant increase in net profit attributable to shareholders after excluding non-recurring gains and losses, which rose by 637.21% year-to-date[6] - Net profit for the third quarter of 2024 was ¥163,076,994.01, a decrease of 45.4% from ¥298,485,079.76 in the same quarter of 2023[15] - The total comprehensive income attributable to the parent company was CNY 185,983,821.75, down from CNY 291,899,926.18 in the previous year, representing a decrease of approximately 36.2%[16] - The company reported a basic earnings per share of CNY 0.34, down from CNY 0.51 year-over-year, reflecting a decline of approximately 33.3%[16] Cash Flow and Liquidity - The net cash flow from operating activities for Q3 2024 was ¥52,825,121.07, a notable improvement from a negative cash flow of ¥9,978,864.61 in the previous year[2] - The net cash flow from operating activities was negative CNY 9,978,864.61, an improvement from negative CNY 169,579,893.12 in the same period last year[18] - The company incurred cash outflows from operating activities totaling CNY 1,314,462,196.71, down from CNY 1,519,821,792.74, a reduction of about 13.5%[18] - The net increase in cash and cash equivalents for the period was CNY 163,721,549.58, compared to CNY 327,047,757.31 in the previous year, reflecting a decrease of approximately 50%[19] - The total cash and cash equivalents at the end of the period increased to CNY 4,335,335,961.46 from CNY 3,426,097,883.74, marking an increase of about 26.5%[19] - The company reported a total cash inflow from financing activities of CNY 429,581,858.96, with a net cash flow from financing activities of CNY 149,286,849.93, compared to a net outflow in the previous year[19] Assets and Liabilities - The total assets of the company at the end of Q3 2024 amounted to ¥8,571,194,405.07, reflecting a 1.38% increase from the end of the previous year[3] - The company's total assets increased to ¥8,571,194,405.07 in Q3 2024, compared to ¥8,454,204,974.00 in Q3 2023, marking a growth of 1.4%[12] - Total liabilities rose to ¥1,218,127,146.43 in Q3 2024, up from ¥1,029,297,739.69 in Q3 2023, indicating an increase of 18.3%[12] - The total equity attributable to shareholders at the end of Q3 2024 was ¥7,238,107,810.77, a slight increase of 0.51% from the previous year[3] - The total equity attributable to shareholders reached ¥7,238,107,810.77 in Q3 2024, compared to ¥7,201,271,019.35 in Q3 2023, showing a slight increase of 0.5%[12] Research and Development - Research and development expenses totaled ¥91,060,774.48 in Q3 2024, an increase of 58.56% year-on-year, accounting for 28.85% of operating revenue[3] - Research and development expenses for the third quarter of 2024 were ¥189,915,613.99, compared to ¥137,493,724.89 in the same quarter of 2023, reflecting a growth of 38.2%[15] - The development expenditure for new technologies reached CNY 85,157,146.77, up from CNY 44,684,836.34, indicating an increase of about 90.5% year-over-year[10] Inventory and Receivables - The company's accounts receivable decreased to CNY 608,556,426.98 from CNY 689,547,683.46, reflecting a decline of approximately 11.5% year-over-year[10] - Inventory increased to CNY 419,030,490.79, up from CNY 376,632,763.99, indicating a growth of about 11.2% compared to the previous year[10] - The total current assets decreased to CNY 5,742,694,872.97 from CNY 5,949,593,915.93, representing a decline of approximately 3.5% year-over-year[10] Government Support and Strategy - The company received government subsidies amounting to ¥12,994,732.67 in Q3 2024, contributing positively to its financial performance[4] - The company has implemented an innovation-driven strategy, leading to substantial growth in key areas such as respiratory, maternal and child health, blood source, and sequencing technologies[6] - The company has not disclosed any new strategies or market expansions during this reporting period[9]

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 圣湘生物科技股份有限公司（以下简称"公司"或"圣湘生物"）的产品副流感病毒 1、2、3 型核酸检测试剂盒（荧光 PCR 法）于近日收到由国家药品监督管理局颁发的 《医疗器械注册证》，现将相关情况公告如下： 证券代码：688289 证券简称：圣湘生物 公告编号：2024-062 圣湘生物科技股份有限公司 关于自愿披露相关产品取得医疗器械注册证 的公告 一、产品注册相关情况 | 注册人名称 | 圣湘生物科技股份有限公司 | | | --- | --- | --- | | 产品名称 | 副流感病毒 | 1、2、3 型核酸检测试剂盒（荧光 PCR 法） | | 预期用途 | | 本产品用于定性检测咽拭子样本中的副流感病毒 1 型、2 型和 3 | | | 型的核酸。 | | | 注册证编号 | | 国械注准 20243402033 | | 注册类别 | | 境内第三类体外诊断试剂 | | 注册证有效期 | | 至 年 月 日 2029 10 15 | 二、对公司的影响 副流感病毒（p ...

一、具体提议情况 为持续践行"以投资者为本"的发展理念，与投资者共享经营发展成果，推动上 市公司高质量发展和投资价值提升，作为公司实际控制人兼董事长，戴立忠先生提议： 证券代码：688289 证券简称：圣湘生物 公告编号：2024-061 圣湘生物科技股份有限公司 关于实际控制人兼董事长提议增强股东分红回报 暨落实公司 2024 年度"提质增效重回报"行动方 案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 圣湘生物科技股份有限公司（以下简称"公司"）于近日收到公司实际控制人兼 董事长戴立忠先生出具的《关于提议增强股东分红回报暨落实公司 2024 年度"提质增 效重回报"行动方案的函》。现将相关情况公告如下： 特此公告。 圣湘生物科技股份有限公司 董事会 在符合《圣湘生物科技股份有限公司章程》（以下简称"《公司章程》"）及《圣 湘生物科技股份有限公司未来三年（2023 年-2025 年）股东分红回报规划》规定的利 润分配原则、保证公司正常经营和长远发展的前提下，自 2024 年度起至 2026 年度， 公司每年以现 ...